Advertisement
AMGN vs PFE
Which Stock Would AI Choose? Amgen (AMGN) vs. Pfizer (PFE) Stock Comparison
Key Takeaways
- Amgen (AMGN) has delivered stronger year-to-date performance of approximately 19.4% compared to Pfizer (PFE)'s 5.6% through late July 2026, outpacing the S&P 500 in both cases.
- Amgen (AMGN) trades near recent highs around $385, supported by consistent dividend declarations including a $2.52 per share quarterly payout, while Pfizer (PFE) offers a higher dividend yield near 6.8-6.9% at prices around $25.
- Amgen (AMGN) benefits from upcoming Q2 2026 earnings on August 4, with expectations for robust revenue, whereas Pfizer (PFE) focuses on pipeline updates and cost management amid lower valuation multiples.
- Both companies operate in the biopharmaceutical sector but differ in scale and focus: Amgen (AMGN) emphasizes targeted therapies with strong momentum, while Pfizer (PFE) maintains broad exposure including vaccines and a higher-yield income profile.
- Recent market activity shows Amgen (AMGN) exhibiting greater price stability and growth relative to Pfizer (PFE), which has traded in a narrower range near multi-year lows on a forward basis.
- Sector sentiment favors established growth names like Amgen (AMGN) in the current environment, though Pfizer (PFE)'s valuation and dividend may appeal to income-oriented investors.
Introduction
This comparison examines Amgen (AMGN) and Pfizer (PFE), two prominent biopharmaceutical companies, to highlight their relative positioning in the current market. Traders and investors seeking exposure to the healthcare sector often evaluate such pairs for differences in growth trajectories, dividend policies, and sensitivity to broader market trends. The analysis draws on recent performance metrics, business developments, and observable sentiment indicators to provide a balanced view suitable for those assessing portfolio allocations or short-term positioning strategies.
AMGN Overview and Recent Performance
Amgen Inc. (AMGN) develops and commercializes innovative therapies in areas including oncology, cardiology, and inflammation. In recent weeks, the stock has demonstrated resilience, closing at approximately $385.16 on July 31, 2026, with year-to-date returns near 19.4% and one-year gains exceeding 34%. Recent market activity has been influenced by consistent dividend announcements, including the third-quarter 2026 payout of $2.52 per share, alongside anticipation surrounding the company's Q2 2026 earnings release scheduled for August 4. These factors have contributed to positive sentiment and outperformance relative to broader indices.
PFE Overview and Recent Performance
Pfizer Inc. (PFE) is a global biopharmaceutical leader with a diversified portfolio spanning vaccines, oncology, and internal medicine. Over the same recent period, the stock closed at $25.01 on July 31, 2026, posting year-to-date returns of about 5.6% and modest one-year gains near 4.6%. Performance has been shaped by ongoing pipeline advancements, such as updates on late-stage candidates, and a focus on maintaining full-year 2026 guidance amid cost discipline. The company's elevated dividend yield has provided support, though price action has remained more contained compared with sector peers.
Trending AI Robots
Tickeron maintains a curated section known as Trending AI Robots, which features the most promising AI trading bots selected from a larger pool. The platform offers hundreds of AI Trading Bots that trade thousands of different tickers, yet only the top performers suited to prevailing conditions appear in this highlighted area. Recent data indicates 25 best AI trending bots chosen from 351 total available options. These bots encompass varied trading styles, strategies, timeframes, performance statistics, and ticker sets, allowing users to explore technical or fundamental approaches across different volatility levels. For additional details on available options, visit Trending AI Robots.
Head-to-Head Comparison
Amgen (AMGN) and Pfizer (PFE) both operate within the biopharmaceutical industry but pursue distinct strategies. Amgen (AMGN) centers on specialized biologics with higher growth potential, reflected in superior recent momentum and returns. Pfizer (PFE) maintains broader diversification, including established products that support a higher dividend yield and lower valuation multiples, potentially appealing in defensive rotations. Risk factors differ as well: Amgen (AMGN) faces typical pipeline and competition pressures but shows greater price consistency, while Pfizer (PFE) contends with post-pandemic normalization and integration challenges that have tempered upside. Market sentiment has favored Amgen (AMGN)'s growth profile in recent weeks, whereas Pfizer (PFE) offers relative value and income characteristics for conservative positioning.
Tickeron AI Verdict
Based on observable factors such as trend consistency, relative momentum, and positioning stability, Tickeron’s AI would likely assign a probabilistic edge to Amgen (AMGN) in the current environment. Stronger recent performance metrics and upcoming catalysts provide a constructive backdrop compared with Pfizer (PFE)'s more measured trajectory. This assessment remains data-driven and subject to evolving market conditions rather than a definitive recommendation.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AMGN is a StrongBuy and PFE is a Buy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
AMGN’s FA Score shows that 4 FA rating(s) are green whilePFE’s FA Score has 3 green FA rating(s).
- AMGN’s FA Score: 4 green, 1 red.
- PFE’s FA Score: 3 green, 2 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
AMGN’s TA Score shows that 4 TA indicator(s) are bullish while PFE’s TA Score has 6 bullish TA indicator(s).
- AMGN’s TA Score: 4 bullish, 4 bearish.
- PFE’s TA Score: 6 bullish, 5 bearish.
Price Growth
AMGN (@Pharmaceuticals: Major) experienced а +6.69% price change this week, while PFE (@Pharmaceuticals: Major) price change was +7.00% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +4.40%. For the same industry, the average monthly price growth was +0.37%, and the average quarterly price growth was +3.27%.
Reported Earning Dates
AMGN is expected to report earnings on Nov 03, 2026.
PFE is expected to report earnings on Nov 03, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (+4.40% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
| AMGN | PFE | AMGN / PFE | |
| Capitalization | 222B | 153B | 145% |
| EBITDA | 16.7B | 17.2B | 97% |
| Gain YTD | 27.377 | 13.017 | 210% |
| P/E Ratio | 25.52 | 35.21 | 72% |
| Revenue | 37.2B | 63.3B | 59% |
| Total Cash | 12B | N/A | - |
| Total Debt | 57.3B | 63.7B | 90% |
AMGN | PFE | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 50 | 44 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 9 Undervalued | 3 Undervalued | |
PROFIT vs RISK RATING 1..100 | 13 | 100 | |
SMR RATING 1..100 | 12 | 77 | |
PRICE GROWTH RATING 1..100 | 13 | 33 | |
P/E GROWTH RATING 1..100 | 41 | 7 | |
SEASONALITY SCORE 1..100 | n/a | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
PFE's Valuation (3) in the Pharmaceuticals Major industry is in the same range as AMGN (9) in the Biotechnology industry. This means that PFE’s stock grew similarly to AMGN’s over the last 12 months.
AMGN's Profit vs Risk Rating (13) in the Biotechnology industry is significantly better than the same rating for PFE (100) in the Pharmaceuticals Major industry. This means that AMGN’s stock grew significantly faster than PFE’s over the last 12 months.
AMGN's SMR Rating (12) in the Biotechnology industry is somewhat better than the same rating for PFE (77) in the Pharmaceuticals Major industry. This means that AMGN’s stock grew somewhat faster than PFE’s over the last 12 months.
AMGN's Price Growth Rating (13) in the Biotechnology industry is in the same range as PFE (33) in the Pharmaceuticals Major industry. This means that AMGN’s stock grew similarly to PFE’s over the last 12 months.
PFE's P/E Growth Rating (7) in the Pharmaceuticals Major industry is somewhat better than the same rating for AMGN (41) in the Biotechnology industry. This means that PFE’s stock grew somewhat faster than AMGN’s over the last 12 months.
| AMGN | PFE | |
|---|---|---|
| RSI ODDS (%) | 4 days ago 58% | 4 days ago 62% |
| Stochastic ODDS (%) | 4 days ago 45% | 4 days ago 54% |
| Momentum ODDS (%) | 4 days ago 66% | 4 days ago 49% |
| MACD ODDS (%) | 4 days ago 66% | 4 days ago 50% |
| TrendWeek ODDS (%) | 4 days ago 61% | 4 days ago 52% |
| TrendMonth ODDS (%) | 4 days ago 59% | 4 days ago 48% |
| Advances ODDS (%) | 6 days ago 59% | 4 days ago 52% |
| Declines ODDS (%) | 8 days ago 50% | 12 days ago 58% |
| BollingerBands ODDS (%) | 4 days ago 49% | 4 days ago 64% |
| Aroon ODDS (%) | 4 days ago 54% | 4 days ago 45% |
Advertisement
PFE and
Correlation & Price change
A.I.dvisor indicates that over the last year, PFE has been loosely correlated with BMY. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if PFE jumps, then BMY could also see price increases.
| Ticker / NAME | Correlation To PFE | 1D Price Change % | ||
|---|---|---|---|---|
| PFE | 100% | +2.14% | ||
| BMY - PFE | 57% Loosely correlated | +0.89% | ||
| MRK - PFE | 55% Loosely correlated | +0.16% | ||
| AMGN - PFE | 53% Loosely correlated | +1.51% | ||
| NVS - PFE | 51% Loosely correlated | +1.37% | ||
| BIIB - PFE | 51% Loosely correlated | +0.80% | ||
More | ||||